Discovery of Potent and Oral Bioavailable MAT2A Inhibitors for the Treatment of MTAP-Deleted Tumors

被引：3
|
作者：
Li, Qun [1 ]
Zang, Yang [1 ]
An, Dan [1 ]
Liu, Lifei [1 ]
Jiang, Wen [1 ]
Liu, Rongchen [1 ]
Su, Jiangtao [2 ]
Yang, Jun [1 ,3 ,4 ]
Li, Lie [1 ]
Zhang, Xuejun [1 ]
机构：
[1] Hubei Biopharmaceut Ind Technol Inst Inc, Wuhan 430075, Hubei, Peoples R China
[2] Hubei Univ Technol, Wuhan 430068, Peoples R China
[3] Humanwell Healthcare Grp Co Ltd, Wuhan 430075, Hubei, Peoples R China
[4] Humanwell Pharmaceut US Inc, Ballwin, MO 63011 USA
来源：
ACS MEDICINAL CHEMISTRY LETTERS | 2023年 / 14卷 / 12期
关键词：
Allosteric Inhibitor; Methionine Adenosyltransferase2A (MAT2A); Methylthioadenosine Phosphorylase (MTAP); 5'-Methylthioadenosine (MTA); 3H-Pyrido[1,2-c]pyrimidin-3-one; METHYLTRANSFERASE; METHIONINE;
D O I：
10.1021/acsmedchemlett.3c00488
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Inhibition of methionine adenosyltransferase 2A (MAT2A) has received significant interest because of its implication as a synthetic lethal target in methylthioadenosine phosphorylase (MTAP)-deleted cancers. Here, we report the discovery of a series of 3H-pyrido-[1,2-c]-pyrimidin-3-one derivatives as novel MAT2A inhibitors. The selected compound 30 exhibited high potency for MAT2A inhibition and a favorable pharmacokinetic profile. Furthermore, in an HCT-116 MTAP-deleted xenograft model, compound 30 showed better in vivo potency than current clinical compound AG-270.
引用
收藏
页码：1876 / 1881
页数：6
相关论文
共 50 条
  • [1] Targeting MAT2A in CDKN2A/MTAP-deleted cancers
    Marjon, Katya
    Kalev, Peter
    Hyer, Marc
    Fletcher, Mark
    Zhang, Peili
    Aguado-Fraile, Elia
    Mandley, Everton
    Konteatis, Zenon
    Travins, Jeremy
    Marks, Kevin
    CANCER RESEARCH, 2019, 79 (13)
  • [2] Vulnerability of MTAP-deleted nasopharyngeal carcinoma to MAT2A inhibition.
    Chan, Yuk Yu
    Bruce, Jeff P.
    Lui, Vivian W. Y.
    Chung, Grace T. Y.
    Tsao, Sai-Wah
    To, Ka-Fai
    Pugh, Trevor J.
    Lo, Kwok-Wai
    CANCER RESEARCH, 2021, 81 (13)
  • [3] Developing brain-penetrating MAT2A inhibitors for MTAP-deleted brain metastatic cancer and GBM
    Ki, Soyoung
    Kim, Jinhee
    Na, Jungtae
    Koh, Ilkyoo
    Cho, Hyunho
    Lee, Ho Yeon
    Jung, Hoiyun
    Cho, Gyeonghi
    Moon, Mijin
    Shin, Yongje
    Park, Sook-Kyung
    CANCER RESEARCH, 2024, 84 (06)
  • [4] A novel and potent MAT2A inhibitor, HM100760, demonstrates antitumor activity in MTAP-deleted cancers
    Kwak, E. J.
    Jung, S. H.
    Hong, D. J.
    Kim, S.
    Park, S.
    Byun, J.
    Lee, W.
    Jeon, S.
    Hong, S.
    Kim, B.
    Ahn, Y. G.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S31 - S31
  • [5] Mat2A Inhibitors decrease growth, increase senescence and p53 stability in MTAP-deleted cancer cells
    Bhola, Neil
    Givmanesh, Atieh
    Wagle, Marie-Claire
    Garcia, Candy
    Vaidya, Kedar
    Cleary, Leah
    Pei, Zhonghua
    Lackner, Mark
    Mounir, Zineb
    CANCER RESEARCH, 2020, 80 (16)
  • [6] Therapeutic vulnerability of MTAP- deleted nasopharyngeal carcinoma by MAT2A inhibitors
    Chan, Yuk-Yu
    Tsang, Chi-Man
    Chung, Grace T. Y.
    To, Ka-Fai
    Zhang, Yi
    Zhang, Xiaodong
    Tang, Jun
    Lo, Kwok Wai
    CANCER RESEARCH, 2023, 83 (07)
  • [7] The mechanistic basis of both deep and durable antitumor activity by combinatorial inhibition of MAT2A and PRMT5 in MTAP-deleted tumors
    Garbett, D.
    Rao, A. A.
    Fischer, M. M.
    Belmontes, B.
    Slemmons, K.
    Appel, M. J.
    Fang, Z.
    Choy, R.
    Tyler, S. R.
    Vivian, J.
    Freyman, Y.
    Magallanes, K.
    Lanham, P.
    Rathore, A.
    Li, A.
    Aubi, O.
    Hughes, P. E.
    Teriete, P.
    White, M. A.
    Neilan, C. L.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S84 - S84
  • [8] Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous MTAP Deletion
    Konteatis, Zenon
    Travins, Jeremy
    Gross, Stefan
    Marjon, Katya
    Barnett, Amelia
    Mandley, Everton
    Nicolay, Brandon
    Nagaraja, Raj
    Chen, Yue
    Sun, Yabo
    Liu, Zhixiao
    Yu, Jie
    Ye, Zhixiong
    Jiang, Fan
    Wei, Wentao
    Fang, Cheng
    Gao, Yi
    Kalev, Peter
    Hyer, Marc L.
    DeLaBarre, Byron
    Jin, Lei
    Padyana, Anil K.
    Dang, Lenny
    Murtie, Joshua
    Biller, Scott A.
    Sui, Zhihua
    Marks, Kevin M.
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (08) : 4430 - 4449
  • [9] Discovery of 2(1H)-Quinoxalinone Derivatives as Potent and Selective MAT2A Inhibitors for the Treatment of MTAP-Deficient Cancers
    Li, Chunzheng
    Lan, Xiaojing
    Li, Xinge
    Fu, Yixian
    Gui, Gang
    Li, Xiaodong
    Shen, Yanyan
    Gan, Zhenjie
    Huang, Min
    Zha, Xiaoming
    JOURNAL OF MEDICINAL CHEMISTRY, 2025, 68 (02) : 1222 - 1244
  • [10] Discovery of novel, potent and orally available MAT2A inhibitors
    Chen, Xuxing
    Li, Jing
    Chen, Yanhong
    CANCER RESEARCH, 2023, 83 (07)
12345